A dual-responsive, hyaluronic acid targeted drug delivery system based on hollow mesoporous silica nanoparticles for cancer therapy. Issue 28 (2nd July 2018)

• Record Type: Journal Article
• Authors: Huang, Lin; Liu, Jia; Gao, Fan; Cheng, Qian; Lu, Bo; Zheng, Hua; Xu, Haixing; Xu, Peihu; Zhang, Xianzheng; Zeng, Xuan
• Is Part Of: Journal of materials chemistry. Volume 6:Issue 28(2018)
• Page Start: 4618
• Page End: 4629
• Publication Date: 2018-07-02
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/c8tb00989a
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : A novel enzyme and redox dual-responsive targeted drug delivery system based on hollow mesoporous silica nanoparticles was developed for cancer therapy. Abstract : In this study, a novel drug delivery system (HMSNs-SS-HA) based on hollow mesoporous silica nanoparticles (HMSNs) was developed for delivering anticancer drugs ( e.g., doxorubicin (DOX)) to targeted tumour cells by using disulfide bonds as redox-sensitive linkers and hyaluronic acid (HA) molecules as both capping and targeting agents. Well-dispersed HMSNs were synthesized with a dimension of around 100 nm. Detailed physical characterization further demonstrated that HMSNs-SS-HA has been successfully constructed. The in vitro drug release experiments displayed the enzyme and redox dual-responsive and sustained drug release properties of DOX loaded HMSNs-SS-HA. Additionally, a series of biological evaluations indicated that these DOX loaded HMSNs-SS-HA could accurately target murine mammary carcinoma (4T1) cells to induce cell apoptosis in vitro and suppress tumour growth in vivo . These results demonstrated that DOX loaded HMSNs-SS-HA was suitable as a potential and efficient drug delivery nanosystem for cancer therapy.